As CEO of ValSource, Whitney Kutney oversees all business operations. She has over 20 years of experience in the pharmaceutical, medical device, and biotech fields encompassing execution activities, management of complex projects, and business oversight. Ms. Kutney holds a Chemical Engineering degree from the University of Notre Dame.

Hal Baseman is Vice President at ValSource Inc. He has over 40 years of experience in pharmaceutical operations, validation, and regulatory compliance. He has held positions in executive management and technical operations at several drug manufacturing and consulting firms.

Hal is the former chair of the PDA Board of Directors, former chair of the PDA Science Advisory Board, former co-leader of the PDA Process Validation Interest Group, and co-leader of the PDA Aseptic Processing Points to Consider and Annex 1 Commenting Task Forces, as well as a long-time member of the PDA Training Research Institute faculty. Baseman holds an MBA in management from LaSalle University and a B.S. in biology from Ursinus College.

Corinn White joined ValSource in 2012. As CFO of ValSource, Inc., Corinn’s responsibilities include assisting in performing all tasks necessary to achieve the organization’s mission and growth plans as part of the management team. She also is responsible for preparing and overseeing fiscal reporting activities as well as analyze and build financial records to improve and accurately report the Company’s financial position.

David Calvaresi is the founder of ValSource, Inc.. He has over 30 years of experience related to the operation and validation of pharmaceutical facilities. This includes three years of operational experience supervising manufacturing and process development at a major biotechnology company.

As Vice President of Business Operations at ValSource, Matteo Taormina oversees all commissioning, qualification and validation (CQV) regions across the US. He has over 25 years of experience in the pharmaceutical and biotech fields, encompassing all CQV activities, management of complex projects, and business oversight.

Matteo has spent over 20 years dedicated to ValSource and has been promoted from Validation Engineer to Project Manager, then Regional Manager, and now VP of Business Operations. He holds a Biology degree, with a minor in Chemistry from Fitchburg State University.

Brian Jordan is the Vice President of Business Development for ValSource. Brian has been with ValSource for more than 25 years and has been in the pharmaceutical, biotech and medical device industries for over 30 years.

Brian’s responsibilities include identifying and developing new business prospects for ValSource throughout the US. Brian leads a team of people in researching and building relationships with new clients. In addition, Brian has extensive, direct experience in the commissioning, qualification, and validation (CQV) of utility, laboratory, process, and control systems.

As Vice President of Human Resources & Recruiting, Carl Barnett brings over 30 years of experience, with 16+ years at ValSource.

Carl provides strategic oversight of Human Resources, including recruiting and talent acquisition, staffing, and immigration policy. He also leads efforts in subcontract resource management, benefits administration, payroll, policy development, compliance, and the administration of our retirement plans including the 401(k) and Employee Stock Ownership Plan (ESOP).

Dr. Kelly Waldron has managed the Quality and Manufacturing Science business units within the consulting division at ValSource, Inc. for 8 years and is a member of the Pharmaceutical Regulatory Science Team (PRST) at the Technological University Dublin (formerly Dublin Institute of Technology) in Dublin, Ireland. Dr. Waldron has particular expertise and a specialized focus on the development and implementation of innovative approaches to quality risk management (QRM) and has authored numerous industry and academic papers on the topic. Her expertise extends to various quality functions in the pharmaceutical, biopharmaceutical, and medical device industries, including quality system design, quality strategy and planning, deviations/investigations, CAPA, change management, data integrity, audit and inspection programs and response, and design control. She holds a BA in biology from Boston University, an MBA in pharmaceutical management from Fairleigh Dickinson University, and a Ph.D. in pharmaceutical regulatory science (thesis in QRM) from the Dublin Institute of Technology.

Marc Glogovsky has managed the microbiology consulting division at ValSource for 8 years. His career spans more than 25 years in the pharmaceutical industry, in various microbiology and management roles. In his current position, Marc focuses on development of contamination control strategies, implementation of rapid microbiological methods (RMMs), and establishing risk-based environmental monitoring programs. He has been an active PDA member for over 25 years and is presently serving on the Board of Directors and on the planning committee for the PDA Regulatory Conference. Additionally, Marc has chaired several Technical Reports and Points to Consider publications and served on both the Science and ATMP Advisory Boards and is the former co-chair of the Microbiology/EM Interest Group. In 2020, Marc was the recipient of the James P. Agalloco award for his efforts at PDA’s Training and Research Institute, and the 2023 Michael Korczynski Award for his support of PDA’s international activities. Marc earned his B.S. in Biology from Monmouth University and his M.S. in Microbiology & Molecular Genetics from Rutgers University.

Hal Baseman:
Hal is the Vice President at ValSource Inc. He has over 40 years of experience in pharmaceutical operations, validation, and regulatory compliance. He has held positions in executive management and technical operations at several drug manufacturing and consulting firms. He is the former chair of the PDA Board of Directors, former chair of the PDA Science Advisory Board, former co-leader of the PDA Process Validation Interest Group, and co-leader of the PDA Aseptic Processing Points to Consider and Annex 1 Commenting Task Forces, as well as a long-time member of the PDA Training Research Institute faculty.

David Calvaresi:

David is the founder of ValSource. He has over 30 years of experience related to the operation and validation of pharmaceutical facilities. This includes three years of operational experience supervising manufacturing and process development at a major biotechnology company.

Diane Blumenthal:

Diane joins the ValSource board of directors with more than 35 years of experience in biopharmaceutical process and product development, clinical and commercial manufacturing, quality control, scientific facilities, program management, and CMC regulatory. Former SVP/Head of Technical Operations at Spark Therapeutics, Ms. Blumenthal is skilled in building and transitioning companies from a start-up research and development organization to a fully integrated biopharmaceutical company with approved commercial manufacturing operations and products. Throughout her career, Ms. Blumenthal has played a key role in the development and commercialization of several well-known pharmaceutical products.

Katherine Oates:

Katherine brings over 25 years of human resources executive experience to the board of directors at ValSource. Ms. Oates is currently the VP of Human Resources for GlaxoSmithKline’s US Pharmaceuticals business. Throughout Ms. Oates’ career with GSK, she has worked with multiple businesses in a variety of HR leadership roles. Ms. Oates’ primary focus throughout her career has been enhancing organizational effectiveness through talent management, workforce engagement, leadership development, and culture.

Robert Radie:

Robert joins the ValSource board of directors with three decades of experience working in both public and private pharmaceutical and biotech companies, and across a range of therapeutic areas. Mr. Radie is currently the Chairman of the Board and CEO at Neuraptive Therapeutics, he has also held senior executive positions in six companies, including serving as Chief Executive Officer of Zyla Life Sciences, Inc. Transmolecular Inc, and Topaz Pharmaceuticals, Inc., which was acquired by Sanofi Pasteur. Mr. Radie also currently serves on the board of directors of several companies, including Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), and Rockwell Medical Technologies Inc. (NASDAQ: RMTI).